(Hypertension. 2000;36:1023.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
From the Department of Cardiovascular Medicine, Cardiovascular Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Correspondence to Yoshitaka Hirooka, MD, PhD, Department of Cardiovascular Medicine, Cardiovascular Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. E-mail hyoshi{at}cardiol.med.kyushu-u.ac.jp
| Abstract |
|---|
|
|
|---|
Key Words: genes nitric oxide brain sympathetic nervous system
| Introduction |
|---|
|
|
|---|
-nitro-L-arginine
methyl ester (L-NAME), another NOS inhibitor, into the NTS
decreased blood pressure, heart rate, and renal sympathetic nerve
activity,3 and the NO donor
Et2N[N(O)NO]Na (NOC 18) increased those
variables.3 Similarly, conflicting results have also
been reported as regard to the effects of NO in the rostral
VLM.2 4 5 However, all of these studies were performed in
anesthetized animals and examined only acute effects of NO or
NOS inhibitors. Long-term effects of increased NO
production in these regions on the regulation of blood pressure
and sympathetic nerve activity in conscious animals remain to be
clarified. Replicant-deficient recombinant adenovirus is now widely used for gene transfer into the brain as well as into the blood vessel.9 10 11 12 Of the viral vectors currently used for gene transfer, adenovirus is considered to offer substantial advantages, including high capability of infecting a variety of differentiated cell types.9 10 11 12 Transfection of replication-defective adenoviral vectors encoding cDNA of endothelial NOS (eNOS) into the brain may provide a way to study the long-term effects of increased NO production in the brain on the regulation of blood pressure and sympathetic nerve activity in conscious animals.
The aim of this study was therefore to determine the effects of increased NO production for much longer periods caused by eNOS overexpression in the NTS on blood pressure, heart rate, and sympathetic nerve activity in conscious rats. For this purpose, we transfected adenovirus vectors encoding either eNOS (AdeNOS) or ß-galactosidase (Adßgal) into the NTS of rats in vivo. Blood pressure and heart rate were continuously monitored with a radiotelemetry system in a conscious state.
| Methods |
|---|
|
|
|---|
0.2 µL/min).
After the injection, all rats recovered from anesthesia and
were unrestrained and free to move in their cages.
|
Construction and Purification of Recombinant Adenovirus
We used adenoviral vectors encoding either bacterial
ß-galactosidase gene or bovine eNOS gene. These adenoviral
vectors were constructed in the Gene Transfer Vector Core Laboratory at
the University of Iowa.10 11 Each gene expression was
driven by the cytomegalovirus early enhancer/promoter with a simian
virus 40 polyadenylation sequence cloned downstream from this reporter.
These vectors were suspended in PBS with 3% sucrose and stored at
-80°C until they were used.
Histochemical Analysis of Gene Expression for
ß-Galactosidase
At day 7 after the gene transfer, the rat was deeply
anesthetized with sodium pentobarbital (100 mg/kg IP) and
perfused transcardially with PBS, followed by 4%
paraformaldehyde in PBS. The brain was removed and the
coronal sections of the medulla were cut serially with a vibratome.
Sections of the medulla (50 µm) were evaluated for
ß-galactosidase expression by X-Gal staining at 37°C for 4 hours.
Immunohistochemistry for eNOS
We performed immunohistochemistry as described
previously.14 At day 3, 7, 14, 21, or 30 after gene
transfer, serial sections of the medulla were obtained as described
above. The sections were rinsed for 30 minutes in PBS. After incubation
overnight in 1% BSA in PBS, the sections were incubated in mouse IgG
monoclonal antibody to human eNOS (1:200) (Transduction Laboratories)
at room temperature overnight and then rinsed 3 times in PBS. After
incubation in biotinylated horse anti-mouse IgG (1:1000, Vector
Laboratories) for 4 hours, the sections were rinsed 3 times in PBS and
incubated for 2 hours in a mixture of streptavidin-conjugated
fluorescein isothiocyanate (1:100, Vector Laboratories) and
propidium iodide (PI, 10 µg/mL). After rinsing 3 times in PBS, the
sections were mounted in Vectashield (Vector Laboratories). BSA (1%),
Triton X-100 (0.3%), and sodium azide (0.05%) were added in each
dilution buffer of the primary and secondary antibodies. Sections
double-stained with eNOS antibody and PI were photographed with a
confocal laser scanning microscope (Bio-Rad MRC 1000), with laser beams
of 488 and 568 nm for excitation. Confocal images were then transferred
to a computer with the image analysis software package NIH
Image.14
As a marker of inflammation, the sections were stained immunohistochemically by antibody against ED1, as described previously.15 The number of cells positive for ED1 was counted and averaged per section.
Western Blot Analysis for eNOS
At day 7 after gene transfer, the coronal block of the brain
containing the injected sites of the NTS were obtained. The NTS tissues
were homogenized and then sonicated in a lysing buffer
containing 40 mmol/L HEPES, 1% Triton X-100, 10% glycerol, and
1 mmol/L phenylmethanesulfonyl fluoride. The tissue lysate
was centrifuged at 6000 rpm for 5 minutes at 4°C with a
microcentrifuge. The lysate was collected, and protein
concentration was determined with a BCA protein assay kit (Pierce). An
aliquot of 20 µg of protein from each sample was separated on 12%
SDS-polyacrylamide gel. Proteins were subsequently transferred
onto polyvinylidene difluoride membranes (Immobilon-P membrane;
Millipore). Membranes were incubated for 2 hours with mouse IgG
monoclonal antibody to eNOS (1:2500). Membranes were then washed and
incubated with a horseradish peroxidaseconjugated horse anti-mouse
IgG antibody (1:10000) for 40 minutes. Immunoreactivity was detected by
enhanced chemiluminescence autoradiography (plus
Western blotting detection kit; Amersham).
Microdialysis and Measurement of NO Metabolites
We measured the production of NO in the NTS as
nitrite/nitrate (NOx) by in vivo microdialysis, as previously described
with some modifications,16 before and at day 7 after gene
transfer. The rat was anesthetized with pentobarbital (50 mg/kg
IP followed by 10 to 20 mg/kg per hour IV), mechanically ventilated
with room air supplemented with oxygen, and placed in a
stereotaxic frame; the dorsal surface of the medulla was
then exposed. A microdialysis probe (A-I-12-01, 1-mm length, Eicom) was
inserted into the NTS (0.6 mm rostral and 0.6 mm lateral to
the calamus scriptorius and 1 mm below the dorsal surface of the
medulla) and was perfused with Ringers solution at a constant flow
rate of 2 µL/min. The perfused dialysates were collected every 10
minutes in a sample loop of an automated sample injector connected to
an automated NO detector high-performance liquid
chromatography system (ENO-10, Eicom), which was based
on a Griess reaction.16 The basal NOx levels were measured
by averaging 3 consecutive stable dialysate samples, which were
obtained
1 hour or more after starting brain perfusion with
Ringers solution. To augment NO production, we used 2 agents
that were administered locally by microdialysis probes. The first agent
was 1 mmol/L of
N-methyl-D-aspartate (NMDA) and the
second agent was 100 µmol/L of L-arginine.
Each drug was dissolved in Ringers solution, and pH was adjusted to
7.4. NMDA or L-arginine was infused for 10
minutes into the NTS through the dialysis probe. After the infusion of
NMDA or L-arginine, the microdialysis probe was
again perfused with Ringers solution.
Radiotelemetry Monitoring of Blood Pressure and Heart Rate
The UA-10 telemetry system (Data Sciences International) was
used to measure systolic blood pressure and heart
rate.17 18 Briefly, the monitoring system consisted of a
transmitter (radiofrequency transducer model TA11PA-C40 or TL11
mol/L2-C50-PXT), receiver panel, consolidation matrix, and the computer
with a MacLab System (AD Instruments). Before the device was implanted,
calibrations were verified to be accurate within ±3 mm Hg. Rats
were anesthetized with sodium pentobarbital, and a flexible
catheter of the transmitter was surgically secured in the abdominal
aorta just below the renal arteries while pointing upstream (against
the flow). Each rat was housed in an individual cage after the
operation, which was placed over the receiver panel that was connected
to the computer for data acquisition. The rats were unrestrained and
free to move in their cages. Blood pressure and heart rate were
recorded continuously for 10 minutes every day between 10 and 11
AM, with a multichannel amplifier and signal converter.
Previous studies have shown that blood pressure and heart rate become
stabilized 7 days after surgery.17 18 Therefore,
microinjection of CSF, vehicle, or adenovirus vectors into the NTS was
performed 7 days after surgery, and telemetry data were collected for a
maximum of 30 days.
To confirm that changes of blood pressure and heart rate caused by AdeNOS transfection was due to the effect of increased NO production, we examined the effect of intracisternal injection of L-NMMA (1 µmol) on blood pressure and heart rate at day 7 after the transfection of Adßgal or AdeNOS into the NTS in rats anesthetized with pentobarbital (50 mg/kg IP followed by 10 to 20 mg/kg per hour IV). This approach and dose of L-NMMA were chosen on the basis of our previous study showing that intracisternal injection of a NOS inhibitor effectively demonstrates the role of endogenous NO in the rapid central adaptation of baroreflex control of sympathetic nerve activity.6
Measurement of Urinary Norepinephrine Excretion
Urine was collected for 24 hours by means of a
metabolic cage. We measured urinary
norepinephrine concentration before and 7 days after the
gene transfer by high-performance liquid
chromatography and calculated urinary
norepinephrine excretion.
Statistical Analysis
All values are expressed as mean±SEM. Two-way ANOVA was used to
compare systolic blood pressure, heart rate, and NOx levels
between the Adßgal-treated group and the other groups. Comparisons
between any two mean values were performed with application of
Bonferronis procedure. A paired t test was used to compare
24-hour urinary norepinephrine excretion before and at day
7 after the gene transfer. Differences were considered to be
significant at the level of P<0.05.
| Results |
|---|
|
|
|---|
Local Expression of eNOS Protein and NOx Production in
NTS
Western blot analysis showed that the expression of eNOS
was significantly increased in the NTS tissue transfected with AdeNOS
at day 7 after gene transfer (Figure 1B). The distribution of
eNOS expression after AdeNOS transfer into the NTS was examined by
immunohistochemistry at day 3, 7, 14, 21, or 30 after the gene
transfer. In the AdeNOS-treated rats, the expression of eNOS protein
was observed locally in the NTS where AdeNOS had been microinjected
(Figure 1, E and F). In the rats treated with AdeNOS, no
eNOS-positive neurons were found in the VLM or the hypothalamus. The
expression of eNOS protein peaked at day 7 and thereafter declined over
time not only by immunohistochemistry but also by Western blot
analysis (at day 0, 3, 5, 7, 14, 21, or 30; n=4 each, data not
shown).
The number of ED1-positive cells per section did not differ between the rats treated with Adßgal and those with AdeNOS (24.8±5.9 versus 21.7±5.0, respectively, n=4 for each).
We also measured the production of NO in the NTS as NOx by in vivo microdialysis before and after gene transfer. The basal level of NOx was significantly higher in the rats treated with AdeNOS at day 7 (20.5±2.0 pmol/20 µL, n=10) than that in the untreated (10.8±1.0 pmol/20 µL, n=12), vehicle-treated (12.4±0.8 pmol/20 µL, n=3), or Adßgal-treated rats (12.1±0.9 pmol/20 µL, n=9). By contrast, the basal level of NOx measured at the site 3 mm apart from the NTS was significantly lower than that in the NTS, and the values were comparable among the 3 groups (AdeNOS-treated group, 5.1±1.2 pmol/20 µL; Adßgal-treated group, 4.2±0.7 pmol/20 µL; untreated group, 4.7±0.9 pmol/20 µL; n=5 for each). NMDA or L-arginine increased NOx production in each group of rats, but the magnitude of the increase in NOx level caused by NMDA or L-arginine was significantly greater in the AdeNOS-treated than in the untreated, vehicle-treated, or Adßgal-treated rats (Figure 2).
|
Blood Pressure and Heart Rate Changes
Figure 3 shows the changes in
systolic blood pressure and heart rate before and after the
microinjection of Adßgal or AdeNOS into the NTS, recorded with
the radiotelemetry system in conscious rats. Systolic blood
pressure and heart rate were decreased in the AdeNOS-treated animals at
day 5 to day 10 after gene transfer. In contrast, these variables
did not change in the Adßgal-treated or vehicle-treated animals (n=2;
data not shown). We examined the effect of intracisternal injection of
L-NMMA on blood pressure and heart rate at day 7 after the Adßgal or
AdeNOS transfection. The magnitudes of the increases in
systolic blood pressure and heart rate evoked by L-NMMA were
significantly greater in the AdeNOS-treated than in the
Adßgal-treated rats (16±4 versus 4±1 mm Hg,
P<0.05; 19±4 versus 1±1 bpm, P<0.01; n=6,
respectively).
|
Urinary Norepinephrine Excretion
Urinary norepinephrine excretion measured at day 7
after gene transfer was significantly decreased in the AdeNOS-treated
but not in the Adßgal-treated animals
(Table).
|
| Discussion |
|---|
|
|
|---|
We transfected adenovirus vectors encoding ß-galactosidase gene or eNOS gene into the NTS in rats. The successful gene transfer into the NTS was confirmed by several methods. First, ß-galactosidase protein expression was confirmed by the histochemical staining of ß-galactosidase in the NTS. Second, eNOS protein expression in the NTS was confirmed by immunohistochemistry and Western blot analysis. The time course of the transfected eNOS protein expression observed in this study was compatible with that in the previous study with adenovirus vectors.19 Third, NOx production in the NTS assessed by in vivo microdialysis was increased at day 7 after eNOS gene transfer. Furthermore, NOx production in the NTS was augmented by NMDA or L-arginine after eNOS gene transfer into the NTS. Finally, changes in blood pressure and heart rate evoked by L-NMMA were greater in the AdeNOS-treated than in the Adßgal-treated rats, indicating that the responses that occurred after eNOS gene transfer were indeed mediated by NO.
We used eNOS, instead of nNOS, which normally exists in the nervous system. However, the purpose of this study was to increase the NO production locally in the NTS for a much longer period in the rats treated with AdeNOS in a conscious state. In the rats treated with AdeNOS, eNOS was expressed in neurons, glia, and other tissues in the NTS where we transfected genes in this study (Figure 1, E and F), as reported previously.10
It may be possible that AdeNOS might have been transported from the NTS to the other regions where the effects of NO might also be exerted.20 In the rats treated with AdeNOS, however, no eNOS-positive neurons were found immunohistochemically in the VLM or the hypothalamus, both of which are known to have direct projections from the NTS. Furthermore, no X-Gal stainingpositive cells were found in the other region of the brain or the other organs. Thus, it is unlikely that adenovirus vector was transfected in regions other than the NTS. Moreover, the effects of the eNOS gene transfer were site-specific, because we did not find any increase in the NOx level at the site 3 mm apart from the NTS. We therefore consider that we were able to transfer genes locally into the NTS in this study.
It is possible that inflammation and cytotoxicity caused by adenovirus infection21 might have affected the present findings. However, the extent of ED1-positive cell infiltration, a marker of inflammation, did not differ significantly between animals treated with Adßgal and those treated with AdeNOS. Moreover, the ß-galactosidase gene transfer did not alter blood pressure, heart rate, urinary norepinephrine excretion, or NOx production. Finally, magnitudes of the increases in systolic blood pressure and heart rate evoked by L-NMMA were greater in the AdeNOS-treated than in the Adßgal-treated rats. These results suggest that changes in these variables in the rats with eNOS gene transfer did not result from inflammation or cytotoxicity but were mediated by the increase in NO production in the NTS.
The major novel finding of this study is that eNOS gene transfer into the NTS decreased blood pressure and heart rate in conscious rats. Blood pressure and heart rate were significantly lowered at day 5 to day 10 and returned to the control levels by day 14 after gene transfer. The time course of blood pressure and heart rate was consistent with that of transgene expression with AdeNOS. The 24-hour urinary norepinephrine excretion was decreased at day 7 after eNOS gene transfer into the NTS, which strongly suggests that eNOS gene transfer into the NTS decreased sympathetic nerve activity in conscious rats. The ß-galactosidase gene transfer into the NTS had no effects on blood pressure, heart rate, NOx production, or urinary norepinephrine excretion. These results indicate that the depressor and bradycardic effects of eNOS gene transfer as well as the decrease in urinary norepinephrine excretion were mediated by the action of NO in the NTS.
Previous studies performed under anesthesia have yielded conflicting results with regard to the modulatory role of NO in the NTS.1 2 3 It has been shown that acute injection of NO donor or its precursor L-arginine into the NTS decreases blood pressure and heart rate in anesthetized rats.2 On the other hand, acute injection of NOS inhibitor (eg, L-NAME or L-NMMA) into the NTS increased1 2 or decreased3 blood pressure and renal sympathetic nerve activity. Anesthesia is known to alter otherwise normal regulatory functions of the brain.22 In this study, we therefore evaluated the effect of increased NO production for a much longer time on blood pressure and heart rate in a conscious state by using a radiotelemetry monitoring system. Our results indicate that increased NO production in the NTS decreases blood pressure, heart rate, and urinary norepinephrine excretion. Changes in heart rate might have been due to NO production in the dorsal motor nucleus of vagus (DMV), which is located close to the NTS.23
The mechanism(s) by which NO in the NTS decreases blood pressure, heart rate, and sympathetic nerve activity remains to be clarified. NO has been suggested to increase the release of excitatory amino acids in the dorsomedial medulla by cGMP-dependent processes.24 There is evidence that in hippocampal slices, NO may mediate the release of the excitatory amino acid through the activation of release-regulating NMDA receptors on presynaptic terminals.25 We have recently shown that NMDA receptor stimulation in the NTS induces NO release, which in turn facilitates glutamate release from presynaptic terminals and thus augments the depressor and bradycardic action of NMDA receptor activation.26 It is known that activation of primary baroreceptor afferents and primary chemoreceptor afferents terminating in the NTS results in depressor and pressor responses, respectively.22 27 There is evidence that in both cases, L-glutamate is the primary neurotransmitter.22 27 We do not know why eNOS transfection in the NTS caused a response similar to that evoked by baroreceptor afferent stimulation rather than chemoreceptor afferent stimulation from our study. However, it has been shown that microinjection of L-glutamate into the NTS produces depressor responses in the rat.22 Thus, we speculate that the relative contribution of L-glutamate in the NTS is greater as baroreceptor stimulation rather than as chemoreceptor stimulation. The other possibility is that eNOS was expressed much more in the baroreceptor afferent terminated area within the NTS because we transfected eNOS at 6 sites of the bilateral NTS. It has been demonstrated that the caudal part of the NTS is important for chemoreceptor stimulation.27 Further experiments will be needed to examine the relative contribution of NO in the NTS between baroreceptor stimulation and chemoreceptor stimulation.
In summary, we developed a technique of eNOS gene transfer into the NTS of rats in vivo. Using this technique, we were able to demonstrate that long-term overexpression of eNOS in the NTS decreases blood pressure, heart rate, and urinary norepinephrine excretion in conscious rats. Our results thus indicate that NO in the NTS exerts an inhibitory effect on sympathetic nerve activity in vivo.
| Acknowledgments |
|---|
Received March 27, 2000; first decision April 25, 2000; accepted June 16, 2000.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Nozoe, Y. Hirooka, Y. Koga, Y. Sagara, T. Kishi, J. F. Engelhardt, and K. Sunagawa Inhibition of Rac1-Derived Reactive Oxygen Species in Nucleus Tractus Solitarius Decreases Blood Pressure and Heart Rate in Stroke-Prone Spontaneously Hypertensive Rats Hypertension, July 1, 2007; 50(1): 62 - 68. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. H. Zucker Novel Mechanisms of Sympathetic Regulation in Chronic Heart Failure Hypertension, December 1, 2006; 48(6): 1005 - 1011. [Full Text] [PDF] |
||||
![]() |
K. Ito, Y. Hirooka, Y. Kimura, Y. Sagara, and K. Sunagawa Ovariectomy Augments Hypertension Through Rho-Kinase Activation in the Brain Stem in Female Spontaneously Hypertensive Rats Hypertension, October 1, 2006; 48(4): 651 - 657. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. T. Talman NO and Central Cardiovascular Control: A Simple Molecule With a Complex Story Hypertension, October 1, 2006; 48(4): 552 - 554. [Full Text] [PDF] |
||||
![]() |
H. Waki, D. Murphy, S. T. Yao, S. Kasparov, and J. F.R. Paton Endothelial NO Synthase Activity in Nucleus Tractus Solitarii Contributes to Hypertension in Spontaneously Hypertensive Rats Hypertension, October 1, 2006; 48(4): 644 - 650. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sakai, Y. Hirooka, H. Shigematsu, T. Kishi, K. Ito, H. Shimokawa, A. Takeshita, and K. Sunagawa Overexpression of eNOS in brain stem reduces enhanced sympathetic drive in mice with myocardial infarction Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2159 - H2166. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Garland, R. Winker, S. M. Williams, L. Jiang, K. Stanton, D. W. Byrne, I. Biaggioni, I. Cascorbi, J. A. Phillips III, P. A. Harris, et al. Endothelial NO Synthase Polymorphisms and Postural Tachycardia Syndrome Hypertension, November 1, 2005; 46(5): 1103 - 1110. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Michalkiewicz, G. Zhao, Z. Jia, T. Michalkiewicz, and M. J. Racadio Central Neuropeptide Y Signaling Ameliorates N({omega})-Nitro-L-Arginine Methyl Ester Hypertension in the Rat Through a Y1 Receptor Mechanism Hypertension, April 1, 2005; 45(4): 780 - 785. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kimura, Y. Hirooka, Y. Sagara, K. Ito, T. Kishi, H. Shimokawa, A. Takeshita, and K. Sunagawa Overexpression of Inducible Nitric Oxide Synthase in Rostral Ventrolateral Medulla Causes Hypertension and Sympathoexcitation via an Increase in Oxidative Stress Circ. Res., February 4, 2005; 96(2): 252 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Lonergan, A. G. Teschemacher, D. Y. Hwang, K.-S. Kim, A. E. Pickering, and S. Kasparov Targeting brain stem centers of cardiovascular control using adenoviral vectors: impact of promoters on transgene expression Physiol Genomics, January 20, 2005; 20(2): 165 - 172. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. K. Walsh, H. Huang, Z. Wang, J. Williams, R. de Crom, R. van Haperen, C. I. Thompson, D. J. Lefer, and T. H. Hintze Control of myocardial oxygen consumption in transgenic mice overexpressing vascular eNOS Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2115 - H2121. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-N. Huang, P.-J. Lu, W.-C. Lo, C.-H. Lin, M. Hsiao, and C.-J. Tseng In Situ Akt Phosphorylation in the Nucleus Tractus Solitarii Is Involved in Central Control of Blood Pressure and Heart Rate Circulation, October 19, 2004; 110(16): 2476 - 2483. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ito, Y. Hirooka, Y. Sagara, Y. Kimura, K. Kaibuchi, H. Shimokawa, A. Takeshita, and K. Sunagawa Inhibition of Rho-Kinase in the Brainstem Augments Baroreflex Control of Heart Rate in Rats Hypertension, October 1, 2004; 44(4): 478 - 483. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ito, Y. Hirooka, T. Kishi, Y. Kimura, K. Kaibuchi, H. Shimokawa, and A. Takeshita Rho/Rho-Kinase Pathway in the Brainstem Contributes to Hypertension Caused by Chronic Nitric Oxide Synthase Inhibition Hypertension, February 1, 2004; 43(2): 156 - 162. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, K. P. Patel, K. G. Cornish, K. M. Channon, and I. H. Zucker nNOS gene transfer to RVLM improves baroreflex function in rats with chronic heart failure Am J Physiol Heart Circ Physiol, October 1, 2003; 285(4): H1660 - H1667. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.-Z. Hsu, P.-J. Chiang, C.-H. Hsu, B.-M. Huang, J.-F. Deng, and M.-Y. Liu The elucidation of epinephrine as an antihypotensive agent in abamectin intoxication Human and Experimental Toxicology, August 1, 2003; 22(8): 433 - 437. [Abstract] [PDF] |
||||
![]() |
K. Ito, Y. Hirooka, K. Sakai, T. Kishi, K. Kaibuchi, H. Shimokawa, and A. Takeshita Rho/Rho-Kinase Pathway in Brain Stem Contributes to Blood Pressure Regulation via Sympathetic Nervous System: Possible Involvement in Neural Mechanisms of Hypertension Circ. Res., June 27, 2003; 92(12): 1337 - 1343. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kishi, Y. Hirooka, Y. Kimura, K. Sakai, K. Ito, H. Shimokawa, and A. Takeshita Overexpression of eNOS in RVLM Improves Impaired Baroreflex Control of Heart Rate in SHRSP Hypertension, February 1, 2003; 41(2): 255 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. A. Janssen and J. F. M. Smits Autonomic control of blood pressure in mice: basic physiology and effects of genetic modification Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2002; 282(6): R1545 - R1564. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-F. Li, S. K. Roy, K. M. Channon, I. H. Zucker, and K. P. Patel Effect of in vivo gene transfer of nNOS in the PVN on renal nerve discharge in rats Am J Physiol Heart Circ Physiol, February 1, 2002; 282(2): H594 - H601. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kishi, Y. Hirooka, K. Ito, K. Sakai, H. Shimokawa, and A. Takeshita Cardiovascular Effects of Overexpression of Endothelial Nitric Oxide Synthase in the Rostral Ventrolateral Medulla in Stroke-Prone Spontaneously Hypertensive Rats Hypertension, February 1, 2002; 39(2): 264 - 268. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. W. Dobrucki, C. L. Cabrera, D. F. Bohr, and T. Malinski Central Hypotensive Action of Clonidine Requires Nitric Oxide Circulation, October 16, 2001; 104(16): 1884 - 1886. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. P. Patel, Y.-F. Li, and Y. Hirooka Role of Nitric Oxide in Central Sympathetic Outflow Experimental Biology and Medicine, October 1, 2001; 226(9): 814 - 824. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kishi, Y. Hirooka, K. Sakai, H. Shigematsu, H. Shimokawa, and A. Takeshita Overexpression of eNOS in the RVLM Causes Hypotension and Bradycardia Via GABA Release Hypertension, October 1, 2001; 38(4): 896 - 901. [Abstract] [Full Text] [PDF] |
||||
|
|